PARSIPPANY, N.J., Dec. 7, 2011 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: [ WPI ]) today announced that under a settlement with Teva Women's Health, Watson has launched Amethia® Lo (levonorgestrel/ethinyl estradiol (0.1mg/0.02mg) and ethinyl estradiol (0.01mg)) tablets, the generic equivalent of Teva Women's Health, Inc.'s LoSEASONIQUE®. Amethia® Lo tablets are indicated for the prevention of pregnancy. Terms of the settlement were not disclosed.

As a "first applicant" to submit a substantially complete ANDA, Watson is eligible for 180 days of shared generic market exclusivity. For the most recent twelve months ending September 30, 2011, LoSEASONIQUE® had sales of approximately $28 million, according to IMS Health data.

About Watson Pharmaceuticals, Inc.

Watson Pharmaceuticals, Inc. is an integrated global specialty pharmaceutical company. The Company is engaged in the development, manufacturing, marketing and distribution of generic pharmaceuticals and specialized branded pharmaceutical products focused on Urology and Women's Health. Watson has operations in many of the world's established and growing international markets.

For press release and other company information, visit Watson Pharmaceuticals' Web site at [ http://www.watson.com ].

Forward-Looking Statement

Statements contained in this press release that refer to non-historical facts are forward-looking statements that reflect Watson's current perspective of existing information as of the date of this release. It is important to note that Watson's goals and expectations are not predictions of actual performance. Actual results may differ materially from Watson's current expectations depending upon a number of factors, risks and uncertainties affecting Watson's business. These factors include, among others, the impact of competitive products and pricing; the timing and success of product launches; difficulties or delays in manufacturing; the availability and pricing of third party sourced products and materials; successful compliance with FDA and other governmental regulations applicable to Watson and its third party manufacturers' facilities, products and/or businesses; changes in the laws and regulations, including Medicare and Medicaid, affecting among other things, pricing and reimbursement of pharmaceutical products; and such other risks and uncertainties detailed in Watson's periodic public filings with the Securities and Exchange Commission, including but not limited to Watson's quarterly report on form 10-Q for the quarter ended September 30, 2011 and Watson's annual report on Form 10-K for the year ended December 31, 2010. Except as expressly required by law, Watson disclaims any intent or obligation to update these forward-looking statements.

LoSEASONIQUE® is a registered trademark of Teva Women's Health, Inc.

(Logo: [ http://photos.prnewswire.com/prnh/20100121/LA41294LOGO ])

cellpadding="0" cellspacing="0" id="convertedTable" style="BORDER-BOTTOM: 1pt; BORDER-LEFT: 1pt; BORDER-COLLAPSE: collapse; BORDER-TOP: 1pt; BORDER-RIGHT: 1pt">

CONTACTS:	Investors:
	Patty Eisenhaur
	(862) 261-8141
	Media:
	Charlie Mayr
	(862) 261-8030

SOURCE Watson Pharmaceuticals, Inc.

[ Back to top ]

N@N

Watson Launches Generic LoSEASONIQUE(R)

Watson Launches Generic LoSEASONIQUE(R)